Related Experiment Videos
Noradrenergic intervention in Alzheimer's disease
T Crook1, E Wilner, A Rothwell
1Memory Assessment Clinics, Inc., Bethesda, MD 20814.
Psychopharmacology Bulletin
|January 1, 1992
Summary
This study found that guanfacine, an alpha2 noradrenergic agonist, did not improve cognitive function in patients with probable Alzheimer's disease (AD). The drug showed no benefits and potentially harmed neuropsychological test performance in early-stage AD.
Area of Science:
- Neuroscience
- Pharmacology
- Gerontology
Background:
- Alzheimer's disease (AD) is a progressive neurodegenerative disorder.
- The noradrenergic system plays a role in cognitive function and is implicated in AD.
- Alpha2 noradrenergic agonists are investigated for potential therapeutic effects in neurological conditions.
Purpose of the Study:
- To evaluate the efficacy of guanfacine, an alpha2 noradrenergic agonist, in patients with probable Alzheimer's disease.
- To assess the safety and tolerability of guanfacine in this patient population.
Main Methods:
- A double-blind, placebo-controlled trial.
- Involved 29 patients with probable Alzheimer's disease.
- Administered a .5-mg daily dose of guanfacine for 13 weeks.
Main Results:
- No evidence of cognitive improvement was observed with guanfacine treatment.
- Some evidence suggested a modest negative impact on neuropsychological test performance.
- The study population was characterized by early-stage cognitive decline.
Conclusions:
- Noradrenergic intervention alone is unlikely to be an effective treatment strategy for Alzheimer's disease.
- Further research may be needed to explore combination therapies or different therapeutic targets.